TOM of this month goes to ACHIEVE trial (n=2,538), which showed that spironolactone 25 mg daily did not reduce CV events or mortality in dialysis patients, and increased risk of severe hyperkalemia #VA by
@nephromommy-akshu.bsky.social. See the latest #ISNTrialWatch summary for details.

#blazerwatch plus Adeera Levin #kidneywk #nephsky

oh that's last yr.....

actually 2 in lancet (GBD and Balci)... 😊 #kidneywk

Richard Haynes- professor at Oxford, nephrologist. Senior author EMPA-k , 3C etc etc…..

Thanks !!!